Cost-Effectiveness of Pazopanib in Advanced Soft Tissue Sarcoma in the United Kingdom
作者： Jordan Amdahl , Stephanie C. Manson , Robert Isbell , Ayman Chit , Jose Diaz
DOI: 10.1155/2014/481071
关键词:
摘要: In the phase III PALETTE trial, pazopanib improved progression-free survival (PFS) compared with placebo in patients advanced/metastatic soft tissue sarcomas (mSTS) who had received prior chemotherapy. We used a multistate model to estimate expected PFS, overall (OS), lifetime STS treatment costs, and quality-adjusted life-years (QALYs) for receiving pazopanib, placebo, trabectedin, ifosfamide, or gemcitabine plus docetaxel as second-line mSTS therapies. The cost-effectiveness of was expressed incremental costs per QALY gained. Estimates PFS/OS, adverse events, utilities were from trial. relative effectiveness other comparators an unadjusted indirect comparison versus pazopanib. Costs published sources. Pazopanib is estimated increase QALYs by 0.128 £7,976 placebo; cost gained be £62,000. Compared chemotherapies, provides similar at lower cost. may not cost-effective but most commonly active treatments, although this conclusion uncertain. Given unmet need effective treatments mSTS, appropriate alternative some currently medications United Kingdom.
hindawi.com
core.ac.uk
utoronto.ca 参考文章(39)
P.G. Casali, N. Abecassis, S. Bauer, R. Biagini, S. Bielack, S. Bonvalot, I. Boukovinas, J V M G Bovee, T. Brodowicz, J.M. Broto, A. Buonadonna, E. De Álava, A.P. Dei Tos, X.G. Del Muro, P. Dileo, M. Eriksson, A. Fedenko, V. Ferraresi, A. Ferrari, S. Ferrari, A.M. Frezza, S. Gasperoni, H. Gelderblom, T. Gil, G. Grignani, A. Gronchi, R.L. Haas, A. Hannu, B. Hassan, P. Hohenberger, R. Issels, H. Joensuu, R.L. Jones, I. Judson, P. Jutte, S. Kaal, B. Kasper, K. Kopeckova, D.A. Krákorová, A. Le Cesne, I. Lugowska, O. Merimsky, M. Montemurro, M.A. Pantaleo, R. Piana, P. Picci, S. Piperno-Neumann, A.L. Pousa, P. Reichardt, M.H. Robinson, P. Rutkowski, A.A. Safwat, P. Schöffski, S. Sleijfer, S. Stacchiotti, K. Sundby Hall, M. Unk, F. Van Coevorden, W. Van der Graaf, J. Whelan, E. Wardelmann, O. Zaikova, J.Y. Blay, Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up† Annals of Oncology. ,vol. 29, pp. 51- 67 ,(2018) , 10.1093/ANNONC/MDY096
Corneel Coens, Winette T. A. van der Graaf, Jean-Yves Blay, Sant P. Chawla, Ian Judson, Roberta Sanfilippo, Stephanie C. Manson, Rachel A. Hodge, Sandrine Marreaud, Judith B. Prins, Iwona Lugowska, Saskia Litière, Andrew Bottomley, Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072). Cancer. ,vol. 121, pp. 2933- 2941 ,(2015) , 10.1002/CNCR.29426
Shirley S Hwang, Victor T Chang, Diane L Fairclough, Janet Cogswell, Basil Kasimis, Longitudinal Quality of Life in Advanced Cancer Patients: Pilot Study Results from a VA Medical Cancer Center Journal of Pain and Symptom Management. ,vol. 25, pp. 225- 235 ,(2003) , 10.1016/S0885-3924(02)00641-3
Natalie B. Jones, Hans Iwenofu, Thomas Scharschmidt, William Kraybill, Prognostic factors and staging for soft tissue sarcomas: an update. Surgical Oncology Clinics of North America. ,vol. 21, pp. 187- 200 ,(2012) , 10.1016/J.SOC.2011.12.003
Thomas E. Delea, Paul Tappenden, Oleg Sofrygin, Dominy Browning, Mayur M. Amonkar, Jon Karnon, Mel D. Walker, David Cameron, Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab European Journal of Health Economics. ,vol. 13, pp. 589- 603 ,(2012) , 10.1007/S10198-011-0323-1
Paul Swinburn, Andrew Lloyd, Paul Nathan, Toni K. Choueiri, David Cella, Maureen P. Neary, Elicitation of health state utilities in metastatic renal cell carcinoma Current Medical Research and Opinion. ,vol. 26, pp. 1091- 1096 ,(2010) , 10.1185/03007991003712258
Tracey A Young, Estimating mean total costs in the presence of censoring: a comparative assessment of methods. PharmacoEconomics. ,vol. 23, pp. 1229- 1242 ,(2005) , 10.2165/00019053-200523120-00007
Marianne Ahlner Elmqvist, Marit S. Jordhøy, Kristin Bjordal, Stein Kaasa, Magnus Jannert, Health-related quality of life during the last three months of life in patients with advanced cancer Supportive Care in Cancer. ,vol. 17, pp. 191- 198 ,(2009) , 10.1007/S00520-008-0477-2
Robert Grimer, Ian Judson, David Peake, Beatrice Seddon, Guidelines for the Management of Soft Tissue Sarcomas Sarcoma. ,vol. 2010, pp. 506182- 506182 ,(2010) , 10.1155/2010/506182
Antoine Italiano, Simone Mathoulin-Pelissier, Axel Le Cesne, Philippe Terrier, Sylvie Bonvalot, Françoise Collin, Jean-Jacques Michels, Jean-Yves Blay, Jean-Michel Coindre, Binh Bui, Trends in survival for patients with metastatic soft-tissue sarcoma† Cancer. ,vol. 117, pp. 1049- 1054 ,(2011) , 10.1002/CNCR.25538